Pure Global

Fragile X syndrome IVD, kit, nucleic acid technique (NAT) - UK MHRA Medical Device Registration

Fragile X syndrome IVD, kit, nucleic acid technique (NAT) is a medical device registered with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) under Device ID 110221. The device is manufactured by Asuragen, Inc. from United States, classified as In Vitro Diagnostic Device. The authorized representative in the UK is Emergo Consulting (UK) Limited .

This page provides comprehensive regulatory information including complete registration details, manufacturer information, device classification, authorized representative details, and related products. Pure Global AI offers free access to 150,962+ UK MHRA medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
MHRA Registered
In Vitro Diagnostic Device
๐Ÿ‡ฌ๐Ÿ‡ง
Fragile X syndrome IVD, kit, nucleic acid technique (NAT)
MHRA Device ID: 110221โ€ขRef: 110221

Device Type

In Vitro Diagnostic Device

Devices

Fragile X syndrome IVD, kit, nucleic acid technique (NAT)

Type

IVD General

Date Registered

Jul 8, 2024

Last Updated

Apr 17, 2024

Manufacturer Information

Address

2150 Woodward Street Suite 100

Austin, Texas, United States

Created Date

Oct 28, 2021

Authorized Representative

Relationship Type

UK Responsible Person

Address

Compass House, Vision Park Histon c/o Cr360 โ€“ UL International

Cambridge, England, United Kingdom

Postcode: CB24 9BZ

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing